Acerus Pharmaceuticals (OTCMKTS:TRLPF) Sets New 52-Week High at $3.14

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPFGet Rating) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $3.14 and last traded at $3.14, with a volume of 0 shares traded. The stock had previously closed at $3.14.

The company has a debt-to-equity ratio of 0.64, a current ratio of 1.35 and a quick ratio of 0.90. The stock has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $0.42.

About Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

Read More

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.